Company Profile
MPM BioImpact is a premier biotechnology investment firm with over 30 years of experience in company creation, venture capital, and impact investing. The firm specializes in transforming scientific discoveries into breakthrough medicines by building biotech companies from the ground up and investing across the full drug development spectrum. Leveraging a team of Entrepreneur Partners with deep expertise in research, development, clinical strategy, and commercialization, MPM BioImpact supports portfolio companies through regulatory challenges and market entry.
Combining the legacy of MPM Capital's biotech venture capital track record with BioImpact's focus on patient outcomes, the firm manages over $3 billion in assets under management across early-stage venture funds, private/public impact funds, and public equities strategies. Their BIOIMPACT FUND™ approach targets companies developing therapies for serious diseases, adhering to global impact investing standards. MPM BioImpact provides strategic guidance, mentorship, and access to extensive networks of industry experts.
Headquartered in Boston with a global presence, the firm invests in innovative areas like RNA medicines, oncology, cell/gene therapies, and precision medicine. Notable portfolio companies include Orna Therapeutics (circular RNA), Aktis Oncology (cancer conjugates), ElevateBio (cell/gene/RNA therapies), and NextPoint Therapeutics (precision cancer therapies).
News & Signals (0)
No linked news activity found for this company.